Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

labatec pharma sa - ceftazidimum - poudre versare soluzione iniettabile - praeparatio sicca: ceftazidimum 500 mg ut ceftazidimum pentahydricum, natrii carbonas pro vitro corresp. natrium 25.2 mg. - malattie infettive - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

labatec pharma sa - ceftazidimum - io. m., polvere per soluzione per iniezione/infusione - praeparatio sicca: ceftazidimum 1 g ut ceftazidimum pentahydricum, natrii carbonas pro vitro corresp. natrium max 50.5 mg. - malattie infettive - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

labatec pharma sa - ceftazidimum - poudre versare soluzione iniettabile/pour perfusione - praeparatio sicca: ceftazidimum 2 g ut ceftazidimum pentahydricum, natrii carbonas pro vitro corresp. natrium max. 101 mg. - malattie infettive - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibatterici per uso sistemico, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..